Trials / Terminated
TerminatedNCT03970616
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- AVEO Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, tolerability, DLTs, MTD, and preliminary anti tumor activity of tivozanib in combination with durvalumab in subjects with advanced HCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tivozanib | Dose level 1: 1.0mg for 21 days followed by 7 days rest; Dose level -1: 1.0mg every other day |
| DRUG | Durvalumab | 1500mg every 28 days |
Timeline
- Start date
- 2019-09-30
- Primary completion
- 2023-04-04
- Completion
- 2023-04-04
- First posted
- 2019-05-31
- Last updated
- 2023-07-12
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03970616. Inclusion in this directory is not an endorsement.